BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Jacobs Receives Vaccine Facility Contract From Netherlands Vaccine Institute


9/6/2006 10:38:48 AM

PASADENA, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Jacobs Engineering Group Inc. (NYSE: JEC - News) announced today that a subsidiary company received a contract from Netherlands Vaccine Institute (NVI) to provide conceptual design services for a facility that will be developed in close cooperation with the Dutch government. Rijks Gebouwen Dienst (RGD), a governmental agency, is owner and architect.

The facility is to be operational by the third quarter of 2009 and will be located at the site of the Netherlands Vaccine Institute at Bilthoven, The Netherlands.

The greenfield facility will produce a range of vaccines to treat the population of The Netherlands. Vaccine bulk products will be formulated and filled in vials and syringes at the new sterile production facility. Operations will include freeze drying of vials, inspection, labeling, packaging, and storage. A second part of the building will house a central sterilization department for the complete site.

Jacobs' conceptual design will embed the latest developments in vaccine production to satisfy Dutch regulations and FDA/EMEA requirements, as well as reflect recent benchmarks and a design-to-cost approach.

In making the announcement, Jacobs Group Vice President Andy Kremer stated, "This challenging assignment is an excellent opportunity to further develop our relationship with both NVI and RGD. We are enthusiastic about becoming their partner for this vital public health project."

NVI CEO Thijs Veerman said, "The project will result in a modern, state-of-the art facility to continue vaccine manufacturing at the highest compliance level."

Jacobs, with over 42,000 employees and revenues approaching $7.0 billion, provides technical, professional, and construction services globally.

Any statements made in this release that are not based on historical fact are forward-looking statements. Although such statements are based on management's current estimates and expectations, and currently available competitive, financial, and economic data, forward-looking statements are inherently uncertain. We, therefore, caution the reader that there are a variety of factors that could cause business conditions and results to differ materially from what is contained in our forward-looking statements. For a description of some of the factors which may occur that could cause actual results to differ from our forward-looking statements please refer to our 2005 Form 10-K, and in particular the discussions contained under Items 1 - Business, 3 - Legal Proceedings, and 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations. We also caution the readers of this release that we do not undertake to update any forward-looking statements made herein.

For additional information contact: Rod Sharp 626.578.6992

Source: Jacobs Engineering Group Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES